A Study of Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) and MK-8527 in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 21, 2025

Primary Completion Date

June 5, 2025

Study Completion Date

June 17, 2025

Conditions

Healthy

Interventions

DRUG

MK-8527

Oral Capsule

DRUG

FTC/TDF

Oral Tablet

Trial Locations (1)

Celerion ( Site 0001), Lincoln

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT06816043 - A Study of Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) and MK-8527 in Healthy Participants | Biotech Hunter | Biotech Hunter